Cell Biotech Co

Cell Biotech Co Equity Growth

The Year-over-Year Equity Growth of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 6.01 %. In the previous year, Year-over-Year Equity Growth was 10.98 % — a change of -45.22% (lower).

Equity Growth

6.01 %

YoY

-45.22%

Last updated:

Year-over-Year Equity Growth of Cell Biotech Co is 2025 6.01 % . Year-over-Year Equity Growth of Cell Biotech Co was 2024 10.98 % . It decreases by -45.22% lower compared to the previous year.

The Cell Biotech Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
17.11 KRW
Jan 1, 2019
-1.91 KRW
Jan 1, 2020
-3.49 KRW
Jan 1, 2021
6.70 KRW
Jan 1, 2022
1.32 KRW
Jan 1, 2023
3.51 KRW
Jan 1, 2024
10.98 KRW
Jan 1, 2025
6.01 KRW
The Cell Biotech Co Equity Growth history
YEAREquity GrowthYoY
6.01 %-45.22%
10.98 %+212.84%
3.51 %+166.54%
1.32 %-80.36%
6.70 %-291.98%
-3.49 %+82.37%
-1.91 %-111.19%
17.11 %+138.18%
7.18 %-67.93%
22.39 %-28.50%
31.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Year-over-Year Equity Growth of Cell Biotech Co is 6.01 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cell Biotech Co

All Key Metrics — Cell Biotech Co